EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLAUR + Neutrophils Drive Anti‐PD‐1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment

Shaoqing Liu, Yanzhao Zhou, Gaoxiang Li, Bingwen Zhu, Fang Wu, Jinxue Zhou, Xiaobing Chen, Bo Qin, Yanxia Gao, Fazhan Wang, Yong Jiang, Wenxin Xu iD

Advanced Science · 2025-10 · 12 (38)

DOI: 10.1002/advs.202507167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.07.2025. Verfasst von Shaoqing Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Microenvironment, Neutrophils. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Central Plains Science and Technology Innovation Young Top Talents Project and Natural Science Foundation of Henan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immune checkpoint inhibitors. However, the role of distinct neutrophil subsets within the TME in mediating tumor resistance to immunotherapy remains poorly understood. Here, the present study reveals that the urokinase‐type plasminogen activator receptor (PLAUR) + neutrophils are enriched in immunotherapy non‐responders and correlate with poor prognosis. Through multi‐omics analyses of clinical cohorts and preclinical models, PLAUR + neutrophils identify as a pivotal driver of immunotherapy resistance by shaping an immunosuppressive TME. Mechanistically, spatial transcriptomics and single‐cell RNA sequencing reveal that PLAUR + neutrophils orchestrate immune evasion by CD8 + T cell exclusion and macrophage‐dependent immune suppression. Through the structure‐based virtual screening, a novel PLAUR inhibitor is identified that could reverse the immunosuppressive phenotype of neutrophils. In various in vivo tumor models, PLAUR inhibitor suppresses tumor growth and potentiates the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy. These results demonstrate that PLAUR + neutrophils serve as a critical regulator of immunotherapy resistance and targeting PLAUR is a promising strategy to augment the efficacy of anti‐PD‐1 therapy in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentNeutrophilsReceptors, Urokinase Plasminogen ActivatorProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmHumansMiceAnimalsImmune Checkpoint InhibitorsImmunotherapy

Stichwörter der Autor:innen

biomarkerhepatocellular carcinomaimmunotherapyneutrophilurokinase‐type plasminogen activator receptor

Substanzen

Receptors, Urokinase Plasminogen ActivatorProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Breast Surgery, Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
  • State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Infection and Immunity, Henan Key Laboratory of Critical Care Medicine, Department…
  • Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
  • State Key Laboratory of Systems Medicine for Cancer, Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
  • Institute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, 451163, China.
  • Department of Immunology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.

ORCID-Profile: Wenxin Xu

Förderung

  • National Natural Science Foundation of China
  • Central Plains Science and Technology Innovation Young Top Talents Project and Natural Science Foundation of Henan Province

Zitieren

APA

Liu, S., Zhou, Y., Li, G., Zhu, B., Wu, F., Zhou, J., Chen, X., Qin, B., Gao, Y., Wang, F., Jiang, Y., & Xu, W. (2025). PLAUR + Neutrophils Drive Anti‐PD‐1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment. Advanced Science, 12(38). https://doi.org/10.1002/advs.202507167

Vancouver

Liu S, Zhou Y, Li G, Zhu B, Wu F, Zhou J, et al. PLAUR + Neutrophils Drive Anti‐PD‐1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment. Advanced Science. 2025;12(38). doi:10.1002/advs.202507167

BibTeX
@article{Liu2025,
  author = {Liu, Shaoqing and Zhou, Yanzhao and Li, Gaoxiang and Zhu, Bingwen and Wu, Fang and Zhou, Jinxue and Chen, Xiaobing and Qin, Bo and Gao, Yanxia and Wang, Fazhan and Jiang, Yong and Xu, Wenxin},
  title = {PLAUR + Neutrophils Drive Anti‐PD‐1 Therapy Resistance in Patients with Hepatocellular Carcinoma by Shaping an Immunosuppressive Microenvironment},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {38},
  doi = {10.1002/advs.202507167}
}
Kostenlos starten →